L’Institut Mérieux has sold its subsidiary ABL Lyon (renamed to Active Biomarkers) to Turenne Santé
Paris – CFI France is pleased to announce that they acted as exclusive financial advisor to l’Institut Mérieux in the sale of its subsidiary ABL Lyon (renamed to Active Biomarkers) to Turenne Santé.
L’Institut Merieux was founded in 1897 in Lyon, is a family holding company dedicated to global public health around the world.
ABL Lyon, now renamed Active Biomarkers, is an integrated bioanalytical laboratory with biomarker and cell-based assay testing capabilities, specialized in well-targeted therapeutic fields such as oncology, infectious diseases, inflammatory pathologies and neurodegenerative diseases.
The company supports multiple biopharmaceutical companies in their clinical research programs (Phases I to IV).
With the support of Turenne Santé, Active Biomarkers will pursue its dynamic growth by gaining new customers. It will also enable to boost significantly its production and R&D capacity, to strengthen its portfolio of proprietary assays, and to evaluate external growth opportunities.
The transaction was announced on 5 November 2020.
Our latest transactions
Healthcare & Life Sciences
has sold a minority stake to
Transaction details
Turin-based radiological company Chiron Group has sold a minority stake to KYIP Capital, accelerating the Group’s expansion
Real Estate & Construction
has been acquired by
Transaction details
BridgeFab, a leading structural steel and metalwork companies in Southeast Queensland, has been acquired by McNab
Software & IT Services
have sold
to
a portfolio company of
Transaction details
Cevinio, a European software company specialising in AI-driven automation for Accounts Payable and Accounts Receivable processes, has been sold to Serrala, a global provider of finance process automation software, supporting end-to-end financial operations through a modular, cloud-ready platform
